Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elke Theander

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Journal of Immunological Methods|November 13, 2017
The use of synthetic peptides for detection of anti-citrullinated protein antibodies in rheumatoid arthritisNicole Hartwig Trier, Bettina Eide Holm, Julie Heiden, et al.
Annals of the Rheumatic Diseases|April 1, 2011
Potential association of muscarinic receptor 3 gene variants with primary Sjogren's syndromeSilke Appel, Stephanie Le Hellard, Ove Bruland, et al.
Plos One|July 22, 2016
Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren's Syndrome and Systemic SclerosisAnders A Bengtsson, Johan Trygg, Dirk M Wuttge, et al.
Annals of the Rheumatic Diseases|February 25, 2022
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio StudyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Annals of the Rheumatic Diseases|January 4, 2023
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Arthritis Research & Therapy|June 23, 2023
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Annals of the Rheumatic Diseases|May 7, 2016
Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studiesRaphaèle Seror, Petra Meiners, Gabriel Baron, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
Annals of the Rheumatic Diseases|June 24, 2021
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study resultsJosef S Smolen, Stefan Siebert, Tatiana V Korotaeva, et al.
Rheumatology (Oxford, England)|August 2, 2015
Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvementsManuel Ramos-Casals, Pilar Brito-Zerón, Raphaèle Seror, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Journal of Immunological Methods|November 13, 2017
The use of synthetic peptides for detection of anti-citrullinated protein antibodies in rheumatoid arthritisNicole Hartwig Trier, Bettina Eide Holm, Julie Heiden, et al.
Annals of the Rheumatic Diseases|April 1, 2011
Potential association of muscarinic receptor 3 gene variants with primary Sjogren's syndromeSilke Appel, Stephanie Le Hellard, Ove Bruland, et al.
Plos One|July 22, 2016
Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren's Syndrome and Systemic SclerosisAnders A Bengtsson, Johan Trygg, Dirk M Wuttge, et al.
Annals of the Rheumatic Diseases|February 25, 2022
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio StudyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Annals of the Rheumatic Diseases|January 4, 2023
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Arthritis Research & Therapy|June 23, 2023
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Annals of the Rheumatic Diseases|May 7, 2016
Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studiesRaphaèle Seror, Petra Meiners, Gabriel Baron, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
Annals of the Rheumatic Diseases|June 24, 2021
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study resultsJosef S Smolen, Stefan Siebert, Tatiana V Korotaeva, et al.
Rheumatology (Oxford, England)|August 2, 2015
Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvementsManuel Ramos-Casals, Pilar Brito-Zerón, Raphaèle Seror, et al.
Pageof 8